Rhodobacter sphaeroides Extract Lycogen™ Attenuates Testosterone-Induced Benign Prostate Hyperplasia in Rats

Int J Mol Sci. 2018 Apr 10;19(4):1137. doi: 10.3390/ijms19041137.


Benign prostate hyperplasia (BPH) is one of the most common urological problems in mid-aged to elderly men. Risk factors of BPH include family history, obesity, type 2 diabetes, and high oxidative stress. The main medication classes for BPH management are alpha blockers and 5α-reductase inhibitors. However, these conventional medicines cause adverse effects. Lycogen™, extracted from Rhodobacter sphaeroides WL-APD911, is an anti-oxidant and anti-inflammatory compound. In this study, the effect of Lycogen™ was evaluated in rats with testosterone-induced benign prostate hyperplasia (BPH). Testosterone injections and Lycogen™ administration were carried out for 28 days, and body weights were recorded twice per week. The testosterone injection successfully induced a prostate enlargement. BPH-induced rats treated with different doses of Lycogen™ exhibited a significantly decreased prostate index (PI). Moreover, the Lycogen™ administration recovered the histological abnormalities observed in the prostate of BPH rats. In conclusion, these findings support a dose-dependent preventing effect of Lycogen™ on testosterone-induced BPH in rats and suggest that Lycogen™ may be favorable to the prevention and management of benign prostate hyperplasia.

Keywords: Lycogen™; Rhodobacter sphaeroides; benign prostate hyperplasia; probiotics.

MeSH terms

  • Animals
  • Biological Products / administration & dosage
  • Biological Products / therapeutic use*
  • Male
  • Prostatic Hyperplasia / drug therapy*
  • Prostatic Hyperplasia / etiology
  • Rats
  • Rats, Sprague-Dawley
  • Rhodobacter sphaeroides / chemistry
  • Testosterone / toxicity


  • Biological Products
  • Lycogen
  • Testosterone